Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

NCT01864538 is registered in ClinicalTrials.gov with ImmunoGenesis as lead sponsor.

NCT NCT01864538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01864538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Lead sponsor
ImmunoGenesis
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2013
Completion date
September 30, 2015
Enrollment
11 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma